Grace Therapeutics, Valuation
| GRCE Stock | 3.44 0.16 4.88% |
At this time, the firm appears to be overvalued. Grace Therapeutics, retains a regular Real Value of USD2.62 per share. The prevalent price of the firm is USD3.44. Our model calculates the value of Grace Therapeutics, from evaluating the firm fundamentals such as total debt of 11.56 M, and Net Income of (12.85 M) as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Grace Therapeutics,'s price fluctuation is very risky at this time. Calculation of the real value of Grace Therapeutics, is based on 3 months time horizon. Increasing Grace Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Grace stock is determined by what a typical buyer is willing to pay for full or partial control of Grace Therapeutics,. Since Grace Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Grace Stock. However, Grace Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.44 | Real 2.62 | Hype 3.3 |
The real value of Grace Stock, also known as its intrinsic value, is the underlying worth of Grace Therapeutics, Company, which is reflected in its stock price. It is based on Grace Therapeutics,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Grace Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Grace Therapeutics, helps investors to forecast how Grace stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Grace Therapeutics, more accurately as focusing exclusively on Grace Therapeutics,'s fundamentals will not take into account other important factors: Grace Therapeutics, Cash |
|
Grace Therapeutics, Total Value Analysis
Grace Therapeutics, is currently forecasted to have valuation of 0 with market capitalization of 0, debt of 11.56 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Grace Therapeutics, fundamentals before making equity appraisal based on enterprise value of the companyGrace Therapeutics, Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The latest return on assets of Grace indicates not a very effective usage of assets in November.Grace Therapeutics, Profitability Analysis
Net Loss for the year was (12.85 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Grace Therapeutics,'s worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Grace Therapeutics, and how it compares across the competition.
About Grace Therapeutics, Valuation
The stock valuation mechanism determines Grace Therapeutics,'s current worth on a weekly basis. Our valuation model uses a comparative analysis of Grace Therapeutics,. We calculate exposure to Grace Therapeutics,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Grace Therapeutics,'s related companies.Grace Therapeutics, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Grace Therapeutics, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 9.4 M |
Complementary Tools for Grace Stock analysis
When running Grace Therapeutics,'s price analysis, check to measure Grace Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grace Therapeutics, is operating at the current time. Most of Grace Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Grace Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grace Therapeutics,'s price. Additionally, you may evaluate how the addition of Grace Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |